← All comparisons
Head-to-head · FAERS comparison

Methotrexate vs Cytarabine: side effects in FDA adverse event reports

How to read this page. FAERS report counts have no denominator; the comparison is of reporting patterns, not of risk. Signals are screened against each FDA label (badges) but not causally assessed. Not medical advice.

At a glance

MethotrexateCytarabine
Drug class–Nucleoside Metabolic Inhibitor
Brand names––
FAERS reports483,09759,730
Serious73%97%
Death outcome37,64013,675
Boxed warningYes WARNING: EMBRYO-FETAL TOXICITY, HYPERSENSITIVITY REACTIONS, BENZYL ALCOHOL TOXICITY, and OTHER SERIOUS ADVERSE REACTIONS • Methotrexate Injection can cause embrYes Only physicians experienced in cancer chemotherapy should use cytarabine injection. For induction therapy patients should be treated in a facility with laborato

Signals both drugs share

No strong shared signal after removing coding and lab terms.

Labeled signals distinctive to Methotrexate

Labeled signals distinctive to Cytarabine

Common questions

Which has more reported side effects, Methotrexate or Cytarabine?

Methotrexate has 483,097 FAERS reports and Cytarabine 59,730. More reports does not mean more dangerous: volume follows how widely and how long a drug has been used, prescription vs over-the-counter status, and publicity. The seriousness share (73% vs 97%) is a better like-for-like signal of the kind of problems reported.

Which side effects do Methotrexate and Cytarabine share?

They share no strong flagged signal after artifacts and lab terms are removed.

Is Methotrexate or Cytarabine safer?

FAERS cannot answer that: it has no denominator and no comparator. Use this page to see which risks are already on each label and which signals are unlabeled, then check the prescribing information and your clinician for your situation.

Sources: openFDA FAERS pair statistics (OpenPV build 2026-09-14), FDA labels via openFDA, openFDA count queries for seriousness and deaths. Pair chosen because it is a commonly searched comparison. Generated 2026-10-08.